Snyder’s Drug Stores achieves ACHC accreditation
ST. LOUIS PARK, Minn. A regional drug store chain recently was accredited to sell diabetic supplies and certain pharmaceuticals to Medicare Part B patients.
Snyder’s Drug Stores was awarded accreditation status by the Accreditation Commission for Health Care, a private, not-for-profit corporation developed by home care and community-based providers to help companies improve business operations and quality of patient care.
Accreditation is a voluntary activity where healthcare organizations submit to peer review of their internal policies, processes and patient care delivery against national standards. By attaining accreditation, Snyders has demonstrated its commitment to maintain a higher level of competency and strive for excellence it its products, services and customer satisfaction.
“We are extremely proud to have earned accreditation status from ACHC,” said Neal Wahlman, Snyder’s president. “It is rewarding to be recognized for our ongoing efforts to provide excellent care to our patients and customers. Our pharmacists and staff work hard every day to meet these exacting standards.”
Medco report: Specialty pharmacy spending driven by cancer drugs
FRANKLIN LAKES, N.J. Cancer drugs will become the biggest driver of specialty pharmacy spending, with global sales of the drugs expected to reach $80 billion by 2012, according to a new report by pharmacy benefit manager Medco Health Solutions.
Spending on cancer drugs increase by 15.1% last year – behind autoimmune disorder and multiple sclerosis drugs – with an overall contribution to drug spending of 5% during the first half of this year.
“Targeted cancer therapies have dramatically reshaped oncology and greatly benefited cancer patients,” Medco chief medical officer Robert Epstein said in a statement. “The newer cancer drugs improve survival rates since they target what fuels the cancer’s growth.”
Cancer drugs also represent a robust pipeline, with more than 800 under investigation. Many of the drugs that the Food and Drug Administration has approved in the last four years – often biotech drugs – have cost $20,000 for 12-week courses of therapy, while some have cost $10,000 a month, though the report said a regulatory approval pathway for biosimilars could help reduce the costs of biotech drug treatments.
Kinney Drugs to purchase Vermont retail pharmacy
GOUVERNEUR, N.Y. A regional retail pharmacy chain in northern New York state will purchase a locally owned store in Vermont.
Kinney Drugs announced Wednesday that it would purchase Vincent’s Drug & Variety, in Waterbury, Vt. The purchase is expected to take place in early January 2010.
“Everyone at Kinney Drugs is excited at the prospect of welcoming Vincent’s Drug employees and customers into our family,” Kinney Drugs president and COO Bridget-ann Hart said in a statement. “It is important to us that this transition be as smooth as possible for both Vincent’s Drug customers and its employees.”
Vincent’s Drug & Variety has been in Waterbury for 98 years.
“The values, health programs and services and community involvement of our two companies are very much aligned,” owner and pharmacist John Vincent said in a statement. “I wholeheartedly trust the people of Kinney Drugs to provide the same level of caring that Washington County has become accustomed to from Vincent’s Drug & Variety.”